Category: My publications

Hum Brain Mapp. 2022 May 24. doi: 10.1002/hbm.25946. Online ahead of print. ABSTRACT Cognitive affective biases describe the tendency to process negative information or positive information over the other. These biases can be modulated by changing extracellular serotonin (5-HT) levels in the brain, for example, by pharmacologically blocking and downregulating the 5-HT transporter (5-HTT), which […]

Transl Psychiatry. 2022 May 16;12(1):204. doi: 10.1038/s41398-022-01969-z. ABSTRACT Previous studies have indicated that antidepressants that inhibit the serotonin transporter reduces oxidative stress. DNA and RNA damage from oxidation is involved in aging and a range of age-related pathophysiological processes. Here, we studied the urinary excretion of markers of DNA and RNA damage from oxidation, 8-oxodG […]

J Psychopharmacol. 2022 May 13:2698811221089035. doi: 10.1177/02698811221089035. Online ahead of print. ABSTRACT BACKGROUND: Major depressive disorder (MDD) is a prevalent neuropsychiatric illness for which it is important to resolve underlying brain mechanisms. Current treatments are often unsuccessful, precipitating a need to identify predictive markers. AIM: We evaluated (1) alterations in brain responses to an emotional […]

Syst Rev. 2022 Apr 15;11(1):68. doi: 10.1186/s13643-022-01952-1. ABSTRACT BACKGROUND: Postpartum depression (PPD) is the most common postpartum psychiatric disorder, affecting 11-15% of new mothers, and initiatives towards early identification and treatment are essential due to detrimental consequences. Family history of psychiatric disorders is a risk factor for developing psychiatric episodes outside the postpartum period, but […]

Front Endocrinol (Lausanne). 2022 Mar 11;13:799675. doi: 10.3389/fendo.2022.799675. eCollection 2022. ABSTRACT BACKGROUND: Hormonal contraceptive (HC) use has been associated with an increased risk of developing a depressive episode. This might be related to HC’s effect on the serotonergic brain system as suggested by recent cross-sectional data from our group, which show that healthy oral contraceptive […]

Front Endocrinol (Lausanne). 2021 Nov 8;12:731994. doi: 10.3389/fendo.2021.731994. eCollection 2021. ABSTRACT BACKGROUND: Women who use oral contraceptives (OCs) may have a higher risk of developing a depression, which is associated with both vulnerability to stress and cognitive dysfunction. OCs disrupt the hypothalamic-pituitary-gonadal (HPG) axis by suppressing endogenous sex steroid production including estradiol. The HPG axis […]

J Psychiatr Res. 2021 Jun 18;141:57-65. doi: 10.1016/j.jpsychires.2021.06.021. Online ahead of print. ABSTRACT While several electroencephalogram (EEG)-based biomarkers have been proposed as diagnostic or predictive tools in major depressive disorder (MDD), there is a clear lack of replication studies in this field. Markers that link clinical features such as disturbed wakefulness regulation in MDD with […]

Neuropsychopharmacology. 2021 Apr 29. doi: 10.1038/s41386-021-01010-9. Online ahead of print. ABSTRACT Premenstrual dysphoric disorder (PMDD) is a psychiatric condition characterized by late luteal phase affective, cognitive, and physical impairment. The disorder causes significant suffering in about 5% of women in their reproductive age. Altered sensitivity of cognitive-affective brain circuits to progesterone and its downstream metabolite […]

Eur Neuropsychopharmacol. 2021 Apr 25;49:101-112. doi: 10.1016/j.euroneuro.2021.03.024. Online ahead of print. ABSTRACT Several electroencephalogram (EEG) biomarkers for prediction of drug response in major depressive disorder (MDD) have been proposed, but validations in larger independent datasets are missing. In the current study, we investigated the prognostic value of previously suggested EEG biomarkers. We gathered data that […]